Which Country Is Best for Cancer Treatment? (2026 Update)

There's no data available to rank "the world's best country for cancer treatment." However, Korea is a country where treatment outcomes can be checked through national cancer registry statistics, and outcomes can be compared by cancer type.

Key Summary

• There is no data in the provided notes that ranks countries by cancer treatment outcomes, so we cannot provide an answer ranking countries against one another.
• Korea's 5-year relative survival rate for stomach cancer is 78.6% (National Cancer Registry Statistics 2019–2023, National Cancer Center Korea), while the US rate is 39.8% (SEER 2016–2022). Because the survey periods and methodologies differ, direct comparison should be approached with caution.
• Korea's 5-year relative survival rate for leukemia is 55.7% (National Cancer Registry Statistics 2019–2023), while the US rate is 68.6% (SEER 2016–2022) — showing the direction can reverse depending on the cancer type.
• These figures represent nationwide averages, not the performance of any specific hospital, and Korean medical law prohibits individual hospitals from using their own treatment outcomes in advertising.
• Survival rates are population averages and are not numbers that predict an individual's outcome; actual prognosis varies depending on stage, histologic type, age, and comorbidities.

Can We Determine Which Country Treats Cancer Best?

• No, this cannot be determined. There is no data in the provided knowledge notes that ranks cancer treatment levels by country; the notes only contain comparative data on 5-year relative survival rates by cancer type.
• Survival rates vary by cancer type. For stomach cancer, Korea is reported higher than the US, while for leukemia, the US is reported higher than Korea. There is no basis in the notes to claim that one country leads in all cancer types.
• Much of the difference comes not only from treatment technology but from differences in early detection rates, the composition of cancer types, and differences in survey periods and methodology. For example, Korea runs a national screening program offering gastroscopy every two years starting at age 40, which is explained as contributing to a higher rate of early-stage stomach cancer diagnosis.

Why Do Survival Rates for the Same Cancer Differ by Country?

• This is due to differences in survey timing and early detection rates. For stomach cancer, Korea's 78.6% (2019–2023) and the US's 39.8% (2016–2022) are national statistics from different periods, and Korea's national screening system is explained as a factor boosting early detection rates.
• Conversely, for leukemia the direction reverses — Korea 55.7% versus the US 68.6%. Blood cancers vary greatly in course depending on subtype (acute versus chronic; leukemia, lymphoma, multiple myeloma), so an overall 'leukemia' figure cannot be directly applied to an individual's situation.
• Both statistics are nationwide averages, not the performance of any particular hospital, so it is appropriate to view them as reference material for broad trends rather than data that determines any one patient's prognosis.

In What Order Is a Treatment Plan Decided?

• Step 1, Biopsy and genetic testing — confirms the histologic type and markers of the cancer (e.g., HER2, EGFR, BCR-ABL, etc.).
• Step 2, Imaging and staging — CT, PET-CT and other scans determine the extent of invasion and whether metastasis is present, establishing the stage.
• Step 3, Determining the treatment plan — based on stage and markers, available options such as surgery, radiation therapy, targeted therapy, chemotherapy, and hematopoietic stem cell transplantation are organized.
• Step 4, Treatment — for early-stage cancer, local treatment (surgery/radiation) is central; for advanced, metastatic, or blood cancers, systemic treatment (chemotherapy/targeted therapy/transplantation) is central.
• Step 5, Follow-up — after treatment, blood tests, imaging, and if necessary bone marrow tests are repeated at set intervals.

FAQ — Can Survival Rate Figures Be Used to Judge Which Country Is Better?

This is not recommended. Survival rates are population averages, not numbers that predict an individual's outcome. Even for the same cancer, the course varies greatly depending on stage, histologic type, age, and comorbidities. In addition, figures such as Korea's 78.6% and the US's 39.8% come from different statistical sources with different periods and methodologies — National Cancer Registry Statistics versus SEER — so they should only be used as a reference for broad direction.

FAQ — Can Hospitals Be Compared and Chosen Based on Their Outcomes?

Under Korean medical law, individual hospitals' treatment outcomes are not used in advertising. The figures cited here are nationwide aggregate statistics compiled by the National Cancer Center Korea's Central Cancer Registry and the US SEER program, not the performance of any specific hospital or medical staff. Which treatment approach is right for you can only be accurately determined through consultation with your treating medical team, based on stage, histologic type, age, and comorbidities.

Sources and Notes

• This article was written based on notes on stomach cancer, blood cancer, targeted therapy, and radiation therapy, National Cancer Registry Statistics 2019–2023 (National Cancer Center Korea's Central Cancer Registry), US SEER 2016–2022, and patient guideline materials from the National Cancer Information Center and NCCN. As data ranking cancer treatment levels by country was not included in the notes, that specific question could not be answered.
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on an individual's condition. Accurate diagnosis and treatment decisions must always be made in consultation with your medical team.